AVITA Medical, Inc. presented new clinical data at the 2026 British Burn Association Annual Meeting in Nottingham, U.K., highlighting the first documented use of RECELL GO in the United Kingdom. The presentation detailed outcomes from 17 patients treated at Stoke Mandeville Hospital, demonstrating the successful application of the automated autologous cell harvesting device in burn and reconstructive surgeries. The findings support the role of RECELL GO in standardizing the preparation of RECELL Spray-On Skin Cells and improving operating room workflow.

The presentation, titled "First U.K. Clinical Experience of RECELL GO, an Automated Autologous Cell Harvesting Device, in Burn Surgery: A Case Series," evaluated the use of AVITA Medical's next-generation automated system across a range of procedures. Investigators selected patients based on injury characteristics and risk factors for healing complications, including larger and deeper wounds, facial injuries, and patients with higher Fitzpatrick skin types.

"RECELL GO is an important next step in autologous cell harvesting technology," said Alexandra Atkins-Murray, Consultant Plastic and Burns Surgeon at Stoke Mandeville Hospital and senior author of the study. "Our early experience demonstrates that the automated system integrates seamlessly into clinical practice while maintaining the clinical outcomes we have come to expect from the RECELL manual system. The ability to standardize preparation and free clinical staff during processing offers meaningful advantages for burn centers and surgical teams across the world."

Clinical Outcomes and Workflow Benefits

In the U.K. case series, all patients successfully received RECELL Spray-On Skin Cells prepared using RECELL GO, either alone or in conjunction with meshed split-thickness skin grafts. Investigators reported uncomplicated donor-site healing, complete graft take, and successful patient discharge without complications. The authors noted workflow benefits, including reduced procedural variability, improved consistency of cell preparation, and greater operating room efficiency.

The investigators concluded that RECELL GO may help expand access to advanced autologous cell therapies by simplifying and standardizing preparation at the point of care, while preserving the clinical benefits associated with RECELL treatment.

Global Adoption and Regulatory Status

"The presentation of this first U.K. clinical experience marks another important milestone in the global adoption of RECELL GO," said Cary Vance, President and Chief Executive Officer of AVITA Medical. "Clinicians are increasingly recognizing the value of technologies that can reduce donor-site burden, support healing, and improve workflow efficiency. We are encouraged by these early results from the U.K. and look forward to continuing to support burn centers worldwide as RECELL GO expands across Europe, the U.K., Australia, New Zealand, and other international markets."

RECELL GO combines a reusable, AC-powered RECELL Processing Device with a single-use RECELL Preparation Kit to automate and standardize the preparation of RECELL Spray-On Skin Cells at the point of care. The system precisely regulates key processing steps to optimize consistency while reducing operator variability and training burden. RECELL GO was CE-marked for commercialization in Europe and the U.K. in 2025 and recently received regulatory authorization in Australia and New Zealand.

In the U.K. and Ireland, RECELL GO is distributed exclusively by Joint Operations Ltd. In the United States, RECELL technology is FDA approved for the treatment of thermal burn and full-thickness skin defects.